Sign in

    Alex Hammond

    Research Analyst at Sidoti & Company, LLC

    Alex Hammond is an Equity Research Analyst at Sidoti & Company, LLC specializing in the coverage of small and micro-cap industrials. He covers companies including Griffon Corporation and CIRCOR International, providing in-depth equity research to institutional clients and contributing to detailed earnings analysis. Hammond began his career in equity research and joined Sidoti & Company early in his professional journey, building a strong track record for insightful market commentary and sector expertise. He holds relevant securities industry licenses and consistently delivers thorough reports to support investor decision-making.

    Alex Hammond's questions to Cibus (CBUS) leadership

    Alex Hammond's questions to Cibus (CBUS) leadership • Q2 2025

    Question

    Alex Hammond from Sidoti & Company, LLC followed up on the 2026 biofragrance commercial ramp, asking if it stems from expanding with the current client or adding new customers. He also requested a comparison of the potential royalty scale for nonallergenic crops and nitrogen use efficiency relative to rice.

    Answer

    Interim CEO Peter Beethen confirmed the 2026 ramp is focused on a single customer, with potential for future expansion. Regarding royalties, he explained that while productivity traits are priced on farm-gate savings, quality traits like nonallergenic crops could command a considerably higher premium, though no specific figures were provided.

    Ask Fintool Equity Research AI

    Alex Hammond's questions to BIOMARIN PHARMACEUTICAL (BMRN) leadership

    Alex Hammond's questions to BIOMARIN PHARMACEUTICAL (BMRN) leadership • Q4 2024

    Question

    An analyst on behalf of Alex Hammond asked about the expected dynamics of patient switching following potential competitor launches for VOXZOGO, and how these dynamics might differ by geography and patient age.

    Answer

    Chief Commercial Officer Cristin Hubbard stated that competition is factored into their models and believes VOXZOGO will have significant 'stickiness.' She cited the trust built from positive patient and physician experiences, a strong safety profile with over 6,000 patient-years of data, and high compliance rates (~95%) as high barriers to switching. She also highlighted BioMarin's entrenched global footprint as a key strategic advantage.

    Ask Fintool Equity Research AI